Renalytix PLC 8-K filings

Renalytix plc will revert to filing as a foreign private issuer (FPI) with the SEC, effective January 1, 2025, after a period of filing as a domestic reporting company.

Renalytix plc successfully passed all resolutions at its Annual General Meeting held on December 19, 2024, including the adoption of the 2024 UK Annual Report and the authorization for the issuance of new shares.

Renalytix plc has amended its 8-K filing to provide revised information regarding a private placement of ordinary shares and the restructuring of certain indebtedness.

Renalytix plc successfully passed all resolutions at its Extraordinary General Meeting, including those related to a capital raise, and appointed a new director while also announcing the resignation of a board member.

Renalytix has successfully raised $11.8 million through a placing and subscription, restructured its debt, and announced plans to delist from Nasdaq to move to the OTCQX market.

Renalytix has been granted an extension until October 25, 2024, to regain compliance with Nasdaq listing requirements and will transfer to the Nasdaq Capital Market effective August 27, 2024.

Renalytix plc has repaid $1.06 million of its convertible bond through the issuance of ordinary shares and American Depositary Shares.

Renalytix plc has changed its independent registered public accounting firm from Ernst & Young to CohnReznick LLP, effective June 19, 2024, as part of a cost-reduction strategy.

Renalytix plc has received notice from Nasdaq that it has failed to regain compliance with listing requirements and faces potential delisting.

Renalytix plc has changed its independent registered public accounting firm from Ernst & Young to CohnReznick LLP, effective June 19, 2024, as part of a cost reduction strategy.

Renalytix has obtained a final Medicare Local Coverage Determination for its kidneyintelX.dkd test, effective August 1, 2024, at a price of $950 per test.

Renalytix plc has appointed Joel R. Jung as Interim Chief Financial Officer, effective June 7, 2024, and granted him stock options as part of his compensation.

Renalytix plc has announced the resignation of its Chief Financial Officer, O. James Sterling, and the appointment of Joel R. Jung as Interim Chief Financial Officer.

Renalytix plc has entered into an agreement to sell up to $15 million of its American Depositary Shares (ADSs) through an at-the-market offering.

Renalytix announced its fiscal third quarter 2024 financial results, showcasing progress in commercial adoption, significant cost reductions, and the initiation of a strategic sale process.

Renalytix plc successfully closed the second tranche of its private placement, raising approximately $7 million in gross proceeds to extend its cash runway into Q4 2024.

Renalytix plc has announced the resignation of its President, Thomas McLain, the appointment of Howard Doran as the new President, and the partial exercise of a share purchase option, raising approximately $0.5 million.

Renalytix plc has issued 3,636,162 ordinary shares, represented by American Depositary Shares, to settle a portion of its convertible bond debt, reducing the outstanding principal by $1.06 million.

Renalytix plc has entered into a securities purchase agreement for a registered direct offering, raising approximately $1 million with a potential for an additional $2.9 million.

Renalytix has secured up to $4 million in financing through a registered direct offering to support its commercial sales activities and ongoing formal sale process.

Renalytix plc has amended its existing bond agreement with CVI Investments, Inc., modifying ownership limitations, trading volumes, and amortization payment terms.

Renalytix's KidneyIntelX test has been included in the final KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease, highlighting its role in risk prediction and personalized treatment.

Renalytix plc successfully completed an upsized equity placing, raising approximately $12 million to extend its cash runway into Q4 2024.

Renalytix has commenced a formal sale process after receiving an unsolicited approach from a strategic diagnostics company, while also exploring financing options.

Renalytix's kidneyintelX.dkd test has been added to a 10-year US government contract and is progressing towards Medicare coverage.

Renalytix reported increased revenue and reduced operating costs for the second quarter of fiscal year 2024, highlighting progress in commercialization and cost management.

Renalytix has announced that the Centers for Medicare and Medicaid Services (CMS) has published a draft Local Coverage Determination (LCD) for its KidneyIntelX and kidneyintelX.dkd tests.

Renalytix's kidneyIntelX.dkd test is under consideration for Medicare coverage, potentially impacting an estimated five million additional patients with Type 2 diabetes and early-stage chronic kidney disease.